ParaGen Technologies
The parent of a family of companies focused on diverse clinical areas including wound care, orthopedics, vascular, and hernia repair.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
$3.0m | Early VC | ||
| Total Funding | 000k | ||
Related Content
ParaGen Technologies, a Columbus, Ohio-based company established in 2016, is focused on the development of tissue engineering technologies. The firm was founded by Flavio Lobato and operates as a joint venture between Nanofiber Solutions, the developer of the core technology, and Ikove Startup Nursery, which provides funding and go-to-market strategy. This structure allows ParaGen to operate as a parent company to a portfolio of medical device companies, each targeting a specific clinical vertical.
The company's core technology revolves around synthetic nanofiber scaffolds that replicate the body's natural extracellular matrix. This scaffold provides structural support for cells, promoting adhesion and proliferation, which are essential for tissue regeneration. The key benefit of this approach is that it aims to combine the advantages of both synthetic and biologic implants while mitigating their respective drawbacks, such as rejection, degradation, and high costs. The technology has demonstrated excellent biointegration and high function regrowth in various applications.
ParaGen's business model is structured to commercialize its platform technology across multiple distinct medical markets through a family of subsidiary companies. This strategy allows for tailored product development and targeted market penetration. The portfolio includes RenovoDerm (wound care), Atreon Orthopedics (orthopedic repair), Vascular Genesis (vascular conduit replacement), and Tarian Medical (hernia repair). This diversification enables investors to capitalize on a variety of verticals within the broader medical device industry. Revenue generation is anticipated through the commercialization of medical devices developed by these subsidiary companies.
Since its inception, ParaGen has achieved several key milestones, including securing a total of $11.6 million in funding over four rounds, with the latest being a Series A round in November 2021. The company's leadership team includes Ross Kayuha as CEO, who brings over 30 years of executive experience; Dr. Jed Johnson as CTO, a recognized expert in tissue engineering; and Ronald Bracken as COO, with extensive experience in medical device R&D.
Keywords: tissue engineering, regenerative medicine, nanofiber scaffolds, medical devices, wound care, orthopedics, vascular repair, hernia repair, platform technology, biointegration